The ‘Magic Mushroom’ ingredient can act as a mental health treatment


Or they might, if tjhey would not be illegal in most states.

Reg became the first U.S. state to create a hallucinogenic compound in magical mushrooms, psilocybin, for mental health treatment in Reagan observation settings.

They have their main evidence with a new study of 24 young adults with major depression published this week in the JAMAMA Psychiatry Journal, which found that two doses of psilocybin significantly reduced depressive symptoms.

Alan Davis, an assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, said: “A news statement.

“Because most other depression treatments take weeks or months and can have unintended effects, these findings could be a game changer if placed in future ‘gold-standard’ placebo-controlled clinical trials.”

Although not without limitations, the study is advanced research to find out how psilocybin can help alleviate mental health problems. Other studies have suggested that the compound may help treat anorexia, obsessive-compulsive disorder, and addiction.

Participants in the Johns Hopkins study experienced depression for about two years before being recruited and had to abandon existing antidepressants. Thirteen participants received silicosibin treatment immediately after enrollment, and 11 participants were placed on a waiting list and received the same treatment after an eight-week delay.

Meztech psilocybin mushrooms are ready in Denver on May 19, 2019.

David Nutt, professor and director of the neuropsychopharmacology unit at the Department of Neuroscience at Imperial College London, said the study provided further evidence of the “rapid and potent effect” of psilocybin. The results could be attributed to the fact that patients knew they would take the drug, expecting a potential increase in the size of the effect, said Knott, who was involved in the research.

A similar 2016 study by Johns Hopkins researchers found that psilocybin could ease depression and anxiety in patients with life-threatening cancer.

“Since there are many types of major depressive disorder that can change the way people react to treatment, I was surprised that most of our study participants found the treatment of psilocybin to be effective.” And a 2016 paper, and a professor at Johns Hopkins University School of Medicine and director of the Johns Hopkins Center for Psychiatric and Consciousness Research.

Silosibins can produce profound changes in visual and auditory perception and consciousness in the hours following ingestion, the study said.

In the United States, occupying compounds is a crime because they are classified as a Scheduled I substance.

For voting in Reg Reagan on the Reagan Health Authority is required to allow licensed, regulatory production and possession of psilocybin for administration through licensed facilities for consumers.

How the brain is affected

How psilocybin affects the brain is still not understood, but Nutt of Imperial Catalyst said that the compound inhibits the negative thinking circuit through the 5HT2Z receptor in the brain.

“Standard anti-depressants protect against stress that leads to depression and make it permanent, but cannot directly penetrate and address the underlying biopsychosocial causes,” he wrote in a paper he agreed earlier this year. And published.
The Canadian government is allowing the use of psychedelic mushrooms to ease the anxiety of 4 temporarily ill patients

“In contrast, psychedelic therapy tends to sound the therapeutic window opened by the brain through the influence of drugs to facilitate insight and emotional liberation.”

He said the substance works with “internecine disorders” such as depression or obsessive-compulsive disorder through which individuals perceive failures or infiltrating thoughts.

Explanation Guy Goodwin, a professor of psychiatry at Xford University, said that serosibin is just behind the serotonin system. Serotonin is a chemical and neurotransmitter in the digestive system, brain and blood system. Which controls mood, social behavior, appetite, sleep, memory and sexual function.

Goodwin, who was not involved with the research, said the main limitation of the Johns Hopkins study was the absence of long-term follow-up – the team chased with participants just four weeks after treatment. For many, depression is a long-term condition, and determining if treatment has a lasting effect is a major missing factor.

Goodwin said that with a study like this, it can be difficult to get out of the process of administering the drug.

Study participants received approximately 11 hours of psychiatry and received the drug under the care of trained professionals and in a setting designed to facilitate the patient.

“You are affected regardless of whether the treatment is effective because everyone takes care of you and discovers you and measures things. People like it and feel good about it. In real terms you do everything but Real drugs ”

Nonetheless, he said a large study is underway that should address the questions raised by preliminary evidence of such a conceptual study.

“This is a nice, small preliminary study with a lot of vulnerabilities but similar positive results promise better things.”

.